Michael Farrell plans 4,991-share ResMed (RMD) sale valued at $1.37M

Rhea-AI Filing Summary

ResMed (RMD) insider Michael Farrell has filed to sell common shares under Rule 144. The notice covers 4,991 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 1,366,436.43 and 145,678,401 common shares outstanding.

The 4,991 shares were acquired on 02/09/2026 via an option originally granted on 11/21/2019, with the purchase price paid in cash. The filing also lists sales over the prior three months: 4,991 common shares on 12/08/2025 for gross proceeds of 1,254,795.79 and 4,991 common shares on 01/07/2026 for 1,240,065.36.

By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about ResMed’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4991	1366436.43	145678401	02/09/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/09/2026	Option Granted - 11/21/2019	Issuer			4991	02/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	12/08/2025	4991	1254795.79
Michael Farrell 9001 Spectrum Center Blvd. San Diego CA 92123	Common	01/07/2026	4991	1240065.36

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Form 144 filing reveal about ResMed (RMD)?

The filing shows Michael Farrell plans to sell 4,991 ResMed common shares under Rule 144. The planned NYSE sale, through Fidelity Brokerage Services, has an aggregate market value of 1,366,436.43, based on the figures disclosed in the notice.

How many ResMed (RMD) shares is Michael Farrell planning to sell?

Michael Farrell has filed to sell 4,991 ResMed common shares. These shares are to be sold on the NYSE via Fidelity Brokerage Services LLC, with the filing reporting an aggregate market value of approximately 1,366,436.43 for this planned transaction.

What prior ResMed (RMD) share sales by Michael Farrell are disclosed?

The notice lists two prior sales of 4,991 ResMed common shares each. One occurred on 12/08/2025 for gross proceeds of 1,254,795.79, and another on 01/07/2026 for gross proceeds of 1,240,065.36.

How were the ResMed (RMD) shares in the new Form 144 acquired?

The 4,991 ResMed common shares were acquired on 02/09/2026 through an option originally granted on 11/21/2019. The filing states that the acquisition was paid for in cash on the same date as the share acquisition.

What does the Form 144 say about material information on ResMed (RMD)?

By signing the notice, the selling security holder represents that he does not know of any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed, consistent with the standard Rule 144 representation language.

How many ResMed (RMD) common shares are reported outstanding in the filing?

The Form 144 reports 145,678,401 ResMed common shares outstanding. This figure provides context for the size of the planned 4,991-share sale relative to the company’s total outstanding common stock base.